Publications

5543 Results

Nivolumab-AVD Improves Progression-Free Survival (PFS) Compared to Brentuximab Vedotin-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL), Results of SWOG S1826

Authors
A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;D Hodgson;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;W Macon;A Perry;A Kovach;L Constine;L Kostakoglu Shields;A Prica;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg
Journal / Conference
Hematology Oncology Vol 41 Issue S2 Supplement; ICML (June 13 to June 17, 2023, Lugano, Switzerland), oral, plenary session
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S1826

A “Functional Cure” May be Achievable in a Subset of Patients with Follicular Lymphoma treated with chemoimmunotherapy: 15-Year Follow-Up of Phase III SWOG-S0016

Authors
M Shadman;H Li;L Rimsza;J Leonard;M Kaminski;K Spier;A Gopal;S Dakhil;M LeBlanc;S Smith;JW Friedberg
Journal / Conference
Hematology Oncology Vol 41 Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland, oral
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S0016

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Authors
J Amengual;P Reagan;H Li;H Saeed;R Vaidya;J Unger;A Danilov;M LeBlanc;JW Friedberg;S Smith
Journal / Conference
Hematology Oncology Vol 41, Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S2207

SWOG 2114: A Randomized Phase II Trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell or Grade IIIB Follicular Lymphoma

Authors
B Hess;H Li;N Hossain;V Beylergil;C Sauter;M Hamadani;J Svoboda;A Major;B Kahl;J Leonard;S Smith;M LeBlanc;P Stiff;JW Friedberg
Journal / Conference
Hematology Oncology Vol 41, Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S2114

S1918: Phase II/III study of R-miniCHOP +/- oral azacitidine in participants age 75 years or older with diffuse large B cell and related lymphomas

Authors
E Brem;H Li;A Beaven;P Caimi;L Cerchietti;R Olin;NL Henry;H Dillon;R Little;M LeBlanc;B Kahl;J Leonard;JW Friedberg;S Smith
Journal / Conference
Hematology Oncology Vol 41 Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S1918

Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

Authors
B Darst;J Shen;R Madduri;A Rodriguez;Y Xiao;X Sheng;E Saunders;T Dadaev;M Brook;T Hoffmann;K Muir;P Wan;L LeMarchand;L Wilkens;Y Wang;J Schleutker;R MacInnis;D Albanes;C Tangen;Z Kote-Jarai;S Watya;J Gaziano;A Justice;D Conti;C Haiman
Journal / Conference
American Journal of Human Genetics Jul 6;110(7):1200-1206
Year
2023
Research Committee(s)
Cancer Control, Prevention, Screening, and and Surveillance
PMID
PMID37292833
PMC
PMC10246022
Study Number(s)
S0000, SWOG-9217

A Randomized Phase 2 Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification: SWOG S1613

Authors
K Raghav;K Guthrie;S Kopetz;B Tan;C Denlinger;M Fakih;M Overman;N Dasari;L Corum;L Hicks;M Patel;B Esparaz;S Kazmi;N Alluri;S Colby;S Gholami;P Gold;EG Chiorean;H Hochster;PA Philip
Journal / Conference
ASCO GI Cancers Symposium (January 19-21, 2023, San Francisco, CA), poster
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
S1613

Phase II study of docetaxel and trametinib in patients with G12C and non-G12C KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT)

Authors
S Gadgeel;J Miao;J Riess;P Mack;G Gerstner;T Burns;A Taj;W Akerley;K Dragnev;N Laudi;J Moon;JE Gray;DR Gandara;KL Kelly
Journal / Conference
Clinical Cancer Research May 26;CCR-22-3947. doi: 10.1158/1078-0432.CCR-22-3947. Online ahead of print
Year
2023
Research Committee(s)
Lung
PMID
PMID37233987
PMC
PMC10526968
Study Number(s)
S1507

Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)

Authors
S Lee;W Fan;A Wang;R Vaidya;M Redman;S Gettinger;L Bazhenova;R Herbst;D Hershman;J Unger
Journal / Conference
JCO Clinical Cancer Informatics Apr;7:e2200165
Year
2023
Research Committee(s)
Lung
PMID
PMID37084329
PMC
PMC10281446
Study Number(s)
S1400I

Subclonal TP53 mutation are frequent and predict resistance to radio-immunotherapy in follicular lymphoma

Authors
R Burack;H Li;D Adlowitz;J Spence;L Rimsza;M Shadman;C Spier;M Kaminski;J Leonard;M LeBlanc;S Smith;J Friedberg
Journal / Conference
Blood Advances Sep 12;7(17):5082-5090
Year
2023
Research Committee(s)
Lymphoma
PMID
PMID37379264
PMC
PMC10471938
Study Number(s)
S0016